These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 23166150)

  • 1. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.
    Guiu S; Michiels S; André F; Cortes J; Denkert C; Di Leo A; Hennessy BT; Sorlie T; Sotiriou C; Turner N; Van de Vijver M; Viale G; Loi S; Reis-Filho JS
    Ann Oncol; 2012 Dec; 23(12):2997-3006. PubMed ID: 23166150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of breast cancer subtypes among African American women in the AMBER consortium.
    Allott EH; Geradts J; Cohen SM; Khoury T; Zirpoli GR; Bshara W; Davis W; Omilian A; Nair P; Ondracek RP; Cheng TD; Miller CR; Hwang H; Thorne LB; O'Connor S; Bethea TN; Bell ME; Hu Z; Li Y; Kirk EL; Sun X; Ruiz-Narvaez EA; Perou CM; Palmer JR; Olshan AF; Ambrosone CB; Troester MA
    Breast Cancer Res; 2018 Feb; 20(1):12. PubMed ID: 29409530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.
    Lundberg A; Lindström LS; Harrell JC; Falato C; Carlson JW; Wright PK; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
    Clin Cancer Res; 2017 Dec; 23(24):7512-7520. PubMed ID: 28972043
    [No Abstract]   [Full Text] [Related]  

  • 5. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B.
    Raj-Kumar PK; Liu J; Hooke JA; Kovatich AJ; Kvecher L; Shriver CD; Hu H
    Sci Rep; 2019 May; 9(1):7956. PubMed ID: 31138829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
    Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
    Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
    Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer.
    Dix-Peek T; Phakathi BP; van den Berg EJ; Dickens C; Augustine TN; Cubasch H; Neugut AI; Jacobson JS; Joffe M; Ruff P; Duarte RAB
    Breast Cancer Res Treat; 2023 May; 199(1):1-12. PubMed ID: 36867282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A three-gene model to robustly identify breast cancer molecular subtypes.
    Haibe-Kains B; Desmedt C; Loi S; Culhane AC; Bontempi G; Quackenbush J; Sotiriou C
    J Natl Cancer Inst; 2012 Feb; 104(4):311-25. PubMed ID: 22262870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is gene array testing to be considered routine now?
    Paik S
    Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
    Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
    Lopez-Tarruella S; Del Monte-Millán M; Roche-Molina M; Jerez Y; Echavarria Diaz-Guardamino I; Herrero López B; Gamez Casado S; Marquez-Rodas I; Alvarez E; Cebollero M; Massarrah T; Ocaña I; Arias A; García-Sáenz JÁ; Moreno Anton F; Olier Garate C; Moreno Muñoz D; Marrupe D; Lara Álvarez MÁ; Enrech S; Bueno Muiño C; Martín M
    Breast Cancer Res Treat; 2024 Jan; 203(1):163-172. PubMed ID: 37773555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5.
    Bago-Horvath Z; Rudas M; Singer CF; Greil R; Balic M; Lax SF; Kwasny W; Hulla W; Gnant M; Filipits M
    Clin Cancer Res; 2020 Nov; 26(21):5682-5688. PubMed ID: 32546648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
    Itoh M; Iwamoto T; Matsuoka J; Nogami T; Motoki T; Shien T; Taira N; Niikura N; Hayashi N; Ohtani S; Higaki K; Fujiwara T; Doihara H; Symmans WF; Pusztai L
    Breast Cancer Res Treat; 2014 Jan; 143(2):403-9. PubMed ID: 24337596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.
    Laible M; Hartmann K; Gürtler C; Anzeneder T; Wirtz R; Weber S; Keller T; Sahin U; Rees M; Ramaswamy A
    BMC Cancer; 2019 Jul; 19(1):694. PubMed ID: 31307414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
    J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining breast cancer intrinsic subtypes by quantitative receptor expression.
    Cheang MC; Martin M; Nielsen TO; Prat A; Voduc D; Rodriguez-Lescure A; Ruiz A; Chia S; Shepherd L; Ruiz-Borrego M; Calvo L; Alba E; Carrasco E; Caballero R; Tu D; Pritchard KI; Levine MN; Bramwell VH; Parker J; Bernard PS; Ellis MJ; Perou CM; Di Leo A; Carey LA
    Oncologist; 2015 May; 20(5):474-82. PubMed ID: 25908555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients.
    Nguyen B; Cusumano PG; Deck K; Kerlin D; Garcia AA; Barone JL; Rivera E; Yao K; de Snoo FA; van den Akker J; Stork-Sloots L; Generali D
    Ann Surg Oncol; 2012 Oct; 19(10):3257-63. PubMed ID: 22965266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
    Fernandez-Martinez A; Pascual T; Perrone G; Morales S; de la Haba J; González-Rivera M; Galván P; Zalfa F; Amato M; Gonzalez L; Prats M; Rojo F; Manso L; Paré L; Alonso I; Albanell J; Vivancos A; González A; Matito J; González S; Fernandez P; Adamo B; Muñoz M; Viladot M; Font C; Aya F; Vidal M; Caballero R; Carrasco E; Altomare V; Tonini G; Prat A; Martin M
    Oncotarget; 2017 Mar; 8(13):21930-21937. PubMed ID: 28423537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
    Chen R; Ye Y; Yang C; Peng Y; Zong B; Qu F; Tang Z; Wang Y; Su X; Li H; Yang G; Liu S
    Breast Cancer Res Treat; 2018 Jul; 170(1):35-43. PubMed ID: 29480449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.